Prediction of Post-ERCP Pancreatitis

Takayoshi Nishino¹ and Fumitake Toki²

¹Institute of Gastroenterology, Department of Medicine, Tokyo Women’s Medical University, School of Medicine, ²Toki Clinic, Japan

1. Introduction

Diagnostic accuracy in regard to biliary and pancreatic diseases has improved markedly since the introduction of computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP)(1,2), but detection of small bile duct cancers and small pancreatic cancers is difficult even by those modalities. Endoscopic retrograde cholangiopancreatography (ERCP) remains the most accurate and reliable procedure for cytodiagnosis and precise staging of biliary and pancreatic neoplasms, and it is indispensable to the endoscopic treatment of biliary and pancreatic diseases.

Pancreatitis remains the most common complication of ERCP and results in substantial morbidity and, occasionally, in death (3-5). The mechanisms responsible for the development of post-ERCP pancreatitis are not fully understood, but they are thought to be multifactorial. A number of specific risk factors have been proposed as predictors of post-ERCP pancreatitis (6-15), and they include patient-, endoscopist-, and procedure-related factors. We therefore think that clear identification of risk factors is facilitated by analyzing the data for diagnostic ERCP and therapeutic ERCP separately.

Early identification of patients who are likely to develop post-procedure pancreatitis is highly desirable in terms of planning long-term follow-up in the hospital and an early therapeutic approach. Hyperamylasemia is common after ERCP, and amylase values have been found to peak between 90 min and 4 h post-ERCP (16,17). Testoni et al. (18) concluded that the serum amylase level measured 4 h after endoscopic sphincterotomy was the most reliable predictor of post-ERCP pancreatitis, and Thomas et al.(19) showed that the 4-h post-procedure amylase level is clinically significant as a predictor of post-ERCP pancreatitis. We therefore hypothesized that the 4-h amylase level is the most accurate amylase value for predicting subsequent pancreatitis.

Several studies (20-24) have demonstrated that the serum lipase level is more sensitive indicator than the serum amylase level for diagnosing other forms of acute pancreatitis, but only a few studies (25-27) have compared measurements of various pancreatic enzymes as a means of predicting post-ERCP pancreatitis. Moreover, it is still unclear whether there are differences in the diagnostic accuracy of pancreatic enzyme levels for predicting post-ERCP pancreatitis according to the procedures, in other words, whether the ERCP is diagnostic or
therapeutic. In the present study we evaluated the 4-h post-ERCP serum amylase level and serum lipase level as predictors of pancreatitis, with special focus on comparison of the two as a means of predicting post-ERCP pancreatitis, in a retrospective single-center design in Japan.

2. Patients and methods

We conducted a retrospective study in a single center by reviewing the 1631 consecutive cases in which ERCP was performed between January 1999 and December 2004 and (male:female ratio = 974:657 (1.48/1); age range 8-97 years old, median 67 years old). Diagnostic ERCP had been performed in 910 cases (male:female ratio = 518:392 (1.32/1); age range 8-90 years old, median 63 years old), and therapeutic ERCP in 721 cases (male: female ratio = 456:265 (1.69/1); age range 19-97 years old, median 67 years old). All patients were enrolled in this study, and there were no exclusion criteria. Diagnostic ERCP included brushing cytology (biliary tract, pancreatic duct) and intraductal ultrasonography (IDUS). Therapeutic ERCP included endoscopic papillary balloon dilatation (EPBD), endoscopic sphincterotomy (EST), stone removal, and bile duct drainage.

All ERCP patients were intravenously infused over 4 hours with one of the following protease inhibitor solutions beginning 30 minutes before the ERCP examination: Gabexate mesilate 200 mg in 0.9% saline, 500 ml, Nafamostat mesilate 20 mg in 0.9 % saline, 500 ml; or Ulinastatin 50,000 U in 0.9 % saline, 500 ml. The choice of inhibitor was at the discretion of the chief physician responsible for the patient’s care.

All patients remained in the hospital for at least 24 hours after the procedure to monitor them for clinical manifestations of pancreatitis. Serum amylase and lipase levels were measured before and 4 and 16-18 hours (the next morning) after ERCP. We evaluated 23 variables, including patient-related factors, an endoscopist-related factor, and procedure-related factors that could be analyzed in detail based on information in the patients’ charts. We also evaluated and compared the 4-h post-ERCP serum amylase level and serum lipase level as predictors of pancreatitis based on receiver-operator characteristic (ROC) curves. To compare the ROC curves, we analyzed only the data from cases in which both amylase and lipase could be measured, in other words, we made a matched pair comparison. We analyzed the data of a total of 1267 patients, consisting of 65 pancreatitis patients and 1202 non-pancreatitis patients. A total of 688 patients, consisting of 39 pancreatitis patients and 649 non-pancreatitis patients had undergone diagnostic ERCP, and a total of 579 patients, consisting of 26 pancreatitis patients and 553 non-pancreatitis patients, had gone therapeutic ERCP.

Data related to the procedures were gathered in a prospective manner, but the global analysis was performed in a retrospective manner.

2.1 Endoscopists

The 1631 ERCP procedures were performed by 11 different endoscopists (median: 57 procedures per endoscopist, range: 8-423). Four of the endoscopists performed about 84% of the procedures, and each of the 4 had performed more than 200 ERCPs before the study. The other 7 endoscopists had performed fewer than 200 ERCPs each before the study.
2.2 Definition

High levels of enzymes was defined as an amylase level (normal range: 40-125 IU/l) and/or lipase level (normal range 13-49 IU/l) above the upper limit of the normal range. The criteria for the diagnosis of post-ERCP pancreatitis were: (1) abdominal pain that persisted for at least 24 hours; (2) a serum amylase level and/or lipase level measured 16-18 hours after the procedure (next morning) that was more than three times the upper limit of the normal range; (3) pancreatic swelling with or without fluid collection on an abdominal US and/or CT examination the next morning. Fulfillment of criterion 1 plus criterion 2 and/or 3 was required to make the diagnosis. Pancreatitis was graded as follows according to the scoring system proposed by the Ministry of Health, Labour and Welfare of Japan (JPN score) (28,29): mild (0 points); moderate (1 point); severe (2 points or more).

The injection pressure of contrast medium into the pancreatic duct was scored as follows based on the degree of pancreatic duct visualization, according to a modification of the criteria proposed by Tsujino et al. (30): 0, no pancreatic duct visualization; 1, visualization of the main pancreatic duct alone; 2, 1 and visualization of primary branches; 3, 2 and visualization of secondary branches; and 4, 3 and/or visualization of acini (acinarization).

2.3 Statistical analysis

In the first step, a univariate analysis was performed by the chi-square method for each of the potential risk factors. In the second step, factors with a p value <0.2 according to the chi-square analysis were included in a multivariate (logistic regression) analysis performed using Statview 5.0 software. A p value <0.05 was considered statistically significant. The odds ratios are reported with their 95% confidence limits.

ROC curve analyses for the serum amylase and lipase values were performed using Medcalc software. We assessed whether the difference in area under two ROC curves was significant based on the methods proposed by Hanley JA et al (31). In short, the difference in area under two ROC curves derived from the same set of patients is calculated as a critical ratio z by using the formula:

\[ z = \frac{(A_1-A_2)}{\sqrt{(SE_1^2+SE_2^2-2rSE_1SE_2)}} \]

where \( A_1 \) is the observed area and \( SE_1 \) is estimated error of the ROC area associated with modality 1, \( A_2 \) and \( SE_2 \) are the corresponding values for modality 2, and \( r \) is a constant calculated from \( (A_1+A_2)/2 \) and \( (rn+ra)/2 \), where \( rn \) is the coefficient for the correlation between modality 1 and modality 2 in the control group (non-pancreatitis group in this study), and \( ra \) is the coefficient for the correlation between modality 1 and modality 2 in the diseased group (pancreatitis group in this study). This quantity \( z \) is then referred to tables of the normal distribution and values of \( z \) above a certain cutoff are taken as evidence of a difference between the ‘true’ ROC areas.

We selected optimal cutoff values for the serum amylase and lipase values as predictors of post-ERCP pancreatitis based on their sensitivity and specificity and especially their positive predictive value (PPV) and negative predictive value (NPV), by using a prior probability value for post-ERCP pancreatitis of 4.2% (incidence rate among the cases in this study as a whole).
3. Results

3.1 Incidence of post-ERCP pancreatitis

Pancreatitis developed after 67 (4.2%) of the 1631 ERCP procedures. According to the JPN scores the pancreatitis was mild after 60 (3.7 %) of the procedures, moderate after 5 (0.3%), and severe after 4 (0.2%). There were no deaths in our series. Pancreatitis developed after 40 (4.4%) of the 910 diagnostic ERCPs, and after 29 (4.0%) of the 721 therapeutic ERCPs. The difference between the incidence of post-ERCP pancreatitis after diagnostic ERCP and after therapeutic ERCP was not statistically significant.

The incidence of post-ERCP pancreatitis after diagnostic ERCP in the Gabexate mesilate group, Nafamostat mesilate group, and Ulinastatin group was 4.7% (31/666), 3.8% (7/184), and 3.3% (2/66), respectively, and there were no statistically significant differences in the incidence of post-ERCP pancreatitis between the three groups. The incidence of post-ERCP pancreatitis after therapeutic ERCP in the Gabexate mesilate group, Nafamostat mesilate group, and Ulinastatin group was 4.4% (19/428), 3.4% (7/209), and 3.6% (3/84), respectively, and there were no statistically significant differences in the incidence of post-ERCP pancreatitis between the three groups.

3.2 Risk factors for post-ERCP pancreatitis

3.2.1 Diagnostic ERCP

3.2.1.1 Univariate analysis

The univariate analysis revealed statistically significant associations between an increased risk of post-ERCP pancreatitis and 4 of the 13 patient-related factors and 4 of the 9 procedure-related factors (Tables 1 and 2). The patient-related factors that significantly increased the risk of pancreatitis were: age 65 years or over, presence of hyperamylasemia and/or hyperlipasemia before ERCP, past or present pancreatitis and IPMN. The significant procedure-related risk factors according to the univariate analysis were: injection of contrast medium into the pancreatic duct score >= 3, brushing cytology in the pancreatic duct, IDUS, and endoscopic nasobiliary drainage (ENBD).

3.2.1.2 Multivariate analysis

Five risk factors were significant according to the multivariate analysis. Two were patient-related factors, age (OR=1.043/1 yr increase in age) and presence of hyperamylasemia and/or hyperlipasemia before ERCP (OR=2.291), and the other three were procedure-related factors, high contrast medium injection pressure into the pancreatic duct (OR=2.406/1 point increase), brushing cytology in the pancreatic duct (OR=4.135), and IDUS (OR=4.373). The R-square value was 0.204.

3.2.2 Therapeutic ERCP

3.2.2.1 Univariate analysis

The univariate analysis revealed a statistically significant association between an increased risk of post-ERCP pancreatitis and only one endoscopist-related factor: inexperienced endoscopist (Tables 3 and 4).
### Table 1. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Diagnostic ERCP: Patient-related Factors (ref 34))

| Patient-related factors                              | Pancreatitis (n=40) | Non-pancreatitis (n=870) | p value |
|------------------------------------------------------|----------------------|---------------------------|---------|
| Significant                                          |                      |                           |         |
| Age (>=65years/<65years)                            | 26/14                | 378/492                   | <0.001  |
| Hyperamylasemia and/or hyperlipasemia (yes/no)      | 18/22                | 184/686                   | <0.001  |
| Past or present pancreatitis (yes/no)               | 9/31                 | 76/773                    | 0.004   |
| IPMN                                                 | 12/28                | 131/739                   | 0.011   |
| Not significant                                      |                      |                           |         |
| Gender (male/female)                                 | 17/23                | 501/369                   | 0.062   |
| Past-post ERCP pancreatitis (yes/no)                | 1/39                 | 6/864                     | 0.200   |
| Past or present cholangitis (yes/no)                 | 1/39                 | 79/791                    | 0.151   |
| Periampullary diverticulum (yes/no)                  | 3/37                 | 66/804                    | 0.984   |
| Chronic pancreatitis (yes/no)                        | 5/35                 | 97/773                    | 0.791   |
| Pancreatic cancer (yes/no)                           | 2/38                 | 108/762                   | 0.160   |
| Pancreas divisum (yes/no)                            | 1/39                 | 30/840                    | 0.746   |
| Anomalous pancreatic-biliary junction (yes/no)       | 2/38                 | 25/845                    | 0.438   |
| Bile duct stone (yes/no)                             | 1/39                 | 40/830                    | 0.532   |

IPMN, intraductal papillary mucinous neoplasia

### Table 2. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Diagnostic ERCP: Procedure-related Factors (n=40) (ref 34))

| Endoscopist-related factor and Procedure-related factors | Pancreatitis (n=40) | Non-pancreatitis (n=870) | p value |
|---------------------------------------------------------|----------------------|---------------------------|---------|
| Significant                                              |                      |                           |         |
| Injection pressure of contrast medium into the pancreatic duct (score 3,4/0-2) | 29/11 | 348/522 | <0.001 |
| Brushing cytology in the pancreatic duct (yes/no)       | 11/29                | 69/801                    | <0.001  |
| IDUS (yes/no)                                           | 8/32                 | 55/815                    | <0.001  |
| ENBD (yes/no)                                           | 1/39                 | 3/867                     | 0.040   |
| Not significant                                          |                      |                           |         |
| Endoscopist experience (<=200 ERCPs/>200 ERCPs)         | 9/31                 | 125/745                   | 0.156   |
| EST (yes/no)                                            | 0/40                 | 1/869                     | 0.830   |
| EPBD (yes/no)                                           | 0/40                 | 0/870                     | N.E.    |
| Bile duct stone exploration (yes/no)                    | 0/40                 | 0/840                     | N.E.    |
| Brushing cytology in the bile duct (yes/no)             | 1/39                 | 44/826                    | 0.466   |
| Biliary stenting (yes/no)                               | 0/40                 | 0/870                     | N.E.    |

ERCP: An Endocopist-related Factor and Procedure-related Factors (ref 34))
IDUS: intraductal ultrasonography; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilation; ENBD, endoscopic nasobiliary drainage
IPMN, intraductal papillary mucinous neoplasia

Table 3. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Therapeutic ERCP: Patient-related Factors (ref34))

| Patient-related factors | Pancreatitis (n=29) | Non-pancreatitis (n=692) | p value |
|-------------------------|---------------------|--------------------------|---------|
| Not Significant         |                     |                          |         |
| Age (>=65years/<65years) | 19/10               | 391/301                  | 0.337   |
| Gender (male/female)    | 21/8                | 435/257                  | 0.300   |
| Hyperamylasemia and/or hyperlipasemia (yes/no) | 8/21               | 207/485                  | 0.788   |
| Past or present pancreatitis(yes/no) | 1/28               | 49/643                   | 0.450   |
| Past-post ERCP pancreatitis(yes/no) | 1/39               | 6/864                    | 0.200   |
| Past or presenting cholangitis (yes/no) | 13/16              | 313/379                  | 0.966   |
| Periampulillary diverticulum (yes/no) | 8/21               | 115/577                  | 0.123   |
| Chronic pancreatitis (yes/no) | 1/28               | 18/674                   | 0.780   |
| Pancreatic cancer (yes/no) | 3/26               | 112/580                  | 0.400   |
| Pancreas divisum (yes/no) | 0/29               | 1/691                    | 0.838   |
| IPMN(yes/no) | 0/29               | 2/690                    | 0.772   |
| Anomalous pancreatic-biliary junction (yes/no) | 1/28               | 6/686                    | 0.165   |
| Bile duct stone (yes/no) | 14/15              | 350/342                  | 0.808   |

Table 4. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Therapeutic ERCP: Endoscopist-related Factor and Procedure-related Factors (ref34))

| Endoscopist-related factor and Procedure-related factors | Pancreatitis (n=29) | Non-pancreatitis (n=692) | p value |
|--------------------------------------------------------|---------------------|--------------------------|---------|
| Significant                                             |                     |                          |         |
| Endoscopist experience (<=200 ERCPs/>200 ERCPs)         | 8/21                | 62/630                   | <0.001  |
| Not significant                                         |                      |                          |         |
| Injection pressure of contrast medium into the pancreatic duct (score 3,4/0-2) | 5/24                | 59/633                   | 0.106   |
| Brushing cytology in the pancreatic duct (yes/no)     | 0/29                | 10/682                   | 0.514   |
| IDUS (yes/no)                                         | 0/29                | 6/686                    | 0.615   |
| EST (yes/no)                                          | 5/24                | 98/594                   | 0.642   |
| EPBD (yes/no)                                         | 8/21                | 114/578                  | 0.118   |
| Bile duct stone exploration (yes/no)                   | 7/22                | 156/536                  | 0.841   |
| Brushing cytology in the bile duct (yes/no)            | 1/28                | 20/672                   | 0.861   |
| Biliary stenting (yes/no)                             | 4/25                | 120/572                  | 0.620   |
| ENBD (yes/no)                                         | 5/24                | 231/461                  | 0.070   |

ERCP: An Endoscopist-related Factor and Procedure-related Factors (ref34))
IDUS, intraductal ultrasonography; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilation; ENBD, endoscopic nasobiliary drainage

Table 4. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Therapeutic
3.2.2.2 Multivariate analysis

Two risk factors were significant according to the multivariate analysis. One was an endoscopist-related factor, inexperienced endoscopist (OR=4.407), and the other was a procedure-related factor, high contrast medium injection pressure into the pancreatic duct (OR=1.693/ 1 point increase). The R-square value was 0.073.

3.2.2.3 Multivariate analysis of the cases as a whole

Six risk factors were significant according to the multivariate analysis for whole cases. Two were patient-related factors, age (OR=1.038/ 1 yr increase in age) and presence of hyperamylasemia and/or hyperlipasemia before ERCP (OR=1.807). One was an endoscopist-related factor, inexperienced endoscopist (OR=2.645), and the other three were procedure-related factors, high contrast medium injection into the pancreatic duct (OR=1.608/1 point increase), brushing cytology in the pancreatic duct (OR=2.605), and IDUS (OR=2.602). R-square value was 0.114.

3.2.3 Prediction of pancreatitis following ERCP by the 4-h post-procedure serum amylase level and lipase level

3.2.3.1 Diagnostic ERCP

The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level after diagnostic ERCP showed good test performance, with an area under the curve of 0.88 (95% CI: 0.85-0.91) and 0.94 (95% CI: 0.92-0.96), respectively (Figure 1). The 4-h

![ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after diagnostic ERCP.](www.intechopen.com)
post-procedure serum lipase level was a more effective predictor of post-ERCP pancreatitis than the amylase level based on the areas under the ROC curves (p=0.025).

3.2.3.2 Therapeutic ERCP

The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level after therapeutic ERCP showed good test performance, with an area under the curve of 0.92 (95% CI: 0.90-0.93) and 0.96 (95% CI: 0.94-0.97), respectively (Figure 2). The 4-h post-procedure serum lipase level was a more effective predictor of post–ERCP pancreatitis than the amylase level, based on the area under the ROC curves (p=0.035).

![ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after therapeutic ERCP.](image)

The area under the curve of the amylase levels was 0.92 (95% CI: 0.90-0.93).
The area under the curve of the lipase levels was 0.96 (95% CI: 0.94-0.97).

**Fig. 2.** ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after therapeutic ERCP.

3.2.3.3 ERCP cases as a whole

The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level after ERCP for the cases as a whole showed good test performance, with an area under the curve of 0.91 (95% CI: 0.89-0.92) and 0.96 (95% CI: 0.94-0.97), respectively (Figures 3). The 4-h post-procedure serum lipase level was a more effective predictor of post–ERCP pancreatitis than the amylase level based on the areas under the ROC curves (p=0.007).
The area under the curve of the amylase levels was 0.91 (95% CI: 0.89-0.92).
The area under the curve of the lipase levels was 0.96 (95% CI: 0.94-0.97).

Fig. 3. ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after ERCP in the cases as a whole.

3.2.3.4 Optimal cutoff values for amylase and lipase

The optimal cutoff values for amylase were five times (625 IU/l) the upper limit of the normal range in the diagnostic ERCP cases, therapeutic ERCP cases, and ERCP cases as a whole based on their sensitivity and specificity and especially on their PPV and NPV (Table 5).

| Amylase level | Sensitivity (%) | Specificity(%) | PPV (%) | NPV (%) | Likelihood ratio |
|---------------|----------------|----------------|---------|---------|-----------------|
| Diagnostic    |                |                |         |         |                 |
| > 3 times     | 82.5           | 70.3           | 10.8    | 98.9    | 2.78            |
| > 4 times     | 77.5           | 79.9           | 14.5    | 98.8    | 3.86            |
| > 5 times     | 70.0           | 85.1           | 17.1    | 98.5    | 4.37            |
| Therapeutic   |                |                |         |         |                 |
| > 3 times     | 90.2           | 72.4           | 14.5    | 99.4    | 3.26            |
| > 4 times     | 86.9           | 79.7           | 17.8    | 99.3    | 4.29            |
| > 5 times     | 85.2           | 86.1           | 21.2    | 99.3    | 6.13            |
| All cases     |                |                |         |         |                 |
| > 3 times     | 89.8           | 72.9           | 12.7    | 99.4    | 3.32            |
| > 4 times     | 84.7           | 80.4           | 16.0    | 99.2    | 4.36            |
| > 5 times     | 78.0           | 85.8           | 19.5    | 98.9    | 5.51            |

Post-ERCP pancreatitis (ref34)). PPV, positive predictive value; NPV, negative predictive value.

Table 5. Diagnostic Accuracy of Various Amylase Cutoff Levels for Predicting
The optimal cutoff values for lipase were ten times (490 IU/l) the upper limit of the normal range in diagnostic ERCP cases, therapeutic ERCP cases, and ERCP cases as a whole based on their sensitivity and specificity and especially on their PPV and NPV (Table 6).

| Lipase level | Sensitivity (%) | Specificity(%) | PPV (%) | NPV (%) | Likelihood ratio |
|--------------|-----------------|----------------|---------|---------|-----------------|
| Diagnostic   |                 |                |         |         |                 |
| > 6 times    | 95.0            | 73.6           | 13.6    | 99.7    | 3.60            |
| > 8 times    | 95.0            | 82.0           | 18.8    | 99.7    | 5.21            |
| > 9 times    | 95.0            | 83.7           | 20.1    | 99.7    | 5.84            |
| > 10 times   | 92.5            | 84.5           | 21.2    | 99.6    | 5.97            |
| Therapeutic  |                 |                |         |         |                 |
| > 6 times    | 96.7            | 81.4           | 18.5    | 99.8    | 5.16            |
| > 8 times    | 96.7            | 85.1           | 22.9    | 99.8    | 6.48            |
| > 9 times    | 96.7            | 86.1           | 24.2    | 99.8    | 6.94            |
| > 10 times   | 95.1            | 86.8           | 26.8    | 99.8    | 7.23            |
| All cases    |                 |                |         |         |                 |
| > 6 times    | 96.6            | 80.8           | 18.1    | 99.8    | 5.05            |
| > 8 times    | 96.6            | 84.8           | 21.8    | 99.8    | 6.34            |
| > 9 times    | 96.6            | 85.9           | 23.1    | 98.8    | 6.85            |
| > 10 times   | 94.9            | 86.4           | 23.8    | 99.7    | 7.04            |

Table 6. Diagnostic Accuracy of Various Lipase Cut-off Levels for Predicting Post-ERCP pancreatitis (ref34)). PPV, positive predictive value; NPV, negative predictive value.

4. Discussion

Pancreatitis remains the most common complication of ERCP, occurring after 1% to 30% of procedures (4-15), and its reported incidence has varied with the thoroughness of follow-up, the definition used, factors related to patient susceptibility, case mix, types of maneuvers performed, and the endoscopist. Rates of pancreatitis of 2% to 9% have been typical in unselected large prospective series (6-14). The subjects of the present study were consecutive patients who underwent diagnostic or therapeutic ERCP, and the incidence rate of pancreatitis was 4.2% in the subjects as a whole, 4.4 % in the diagnostic ERCP group, 4.0 % in therapeutic ERCP group. These figures are comparable to those reported in recent prospective studies in which the definition and study population were similar to those in our study.

A number of specific risk factors, acting independently or in concert, have been proposed as predictors of post-ERCP pancreatitis (6-14). The present study assessed 23 risk factors that included patient-related, procedure-related, and endoscopist-related variables. The results of the multivariate analysis showed that older age, hyperamylasemia and/or hyperlipasemia before ERCP, endoscopist experience with fewer than 200 ERCPs, high contrast medium injection pressure into the pancreatic duct, brushing cytology in the pancreatic duct, and IDUS each increased risk independently. The results of this study also demonstrated that the risk of post-ERCP pancreatitis is as much related to patient characteristics as to endoscopic technique and/or maneuvers, as previously reported (6-10,14). However, the limitation of the present study is that it was a retrospective study. In spite of the fact that data were obtained from consecutive ERCP cases, minimal bias must be taken into account.
Previous studies have suggested that early hyperamylasemia is useful as a predictor of post-ERCP pancreatitis (18,19,32,33). Thomas et al. (19) found that a 4-h amylase level threefold higher than normal was a useful predictor of pancreatitis and had a sensitivity and specificity of 70% and 95.3%, respectively. Testoni et al. (18) reported that a serum amylase level fivefold higher than normal 4 h after the procedure is a reliable predictor of post-procedure pancreatitis, with a sensitivity of 68.4%. In the present study the ROC of both the 4-h amylase level and the 4-h lipase level after diagnostic ERCP showed good test performance, with an area under the curve of 0.88 and 0.94, respectively, and the ROC of both the 4-h amylase level and the 4-h lipase level after therapeutic ERCP also showed good test performance, with an area under the curve of 0.92 and 0.96, respectively. In addition, the ROC of both the 4-h amylase and the 4-h lipase level after ERCP in the cases as a whole showed good test performance, with an area under the curve of 0.91 and 0.96, respectively. The optimal cutoff values for the amylase level after diagnostic ERCP, therapeutic ERCP, and ERCP as a whole were 5 times (625 IU/l) the upper limit of the normal range, and the sensitivity and specificity of the cutoff value for the as a whole cases was 78.0% and 85.8%, respectively. The optimal cutoff values for the lipase level after diagnostic ERCP, therapeutic ERCP, and ERCP as a whole cases were 10 times (490 IU/l) the upper limit of the normal range, and their sensitivity and specificity in the cases as a whole were 94.9% and 86.4%. The results of this study confirmed that the 4-h post-procedure serum amylase and lipase level are good predictors of pancreatitis both after diagnostic ERCP and after therapeutic ERCP.

Comparisons of measurements of various pancreatic enzymes as a means of detecting of acute pancreatitis other than post-ERCP pancreatitis have shown that the blood lipase level is almost as sensitive as the total blood amylase level and has better specificity (20). Other studies (21-23) have demonstrated that the blood lipase level is more sensitive than the blood amylase level, and still another study concluded that the blood lipase level is an important diagnostic indicator for acute pancreatitis and that measuring it should be given top priority (24). By contrast, few studies have compared measurements of various pancreatic enzymes as a means of diagnosing post-procedure pancreatitis (25-27). Panteghini et al. (25) found that the serum lipase level increased faster than the levels of the other enzymes measured and that the average peak in lipase level was the highest in post-procedure pancreatitis. Doppl et al. (26) concluded that serum lipase measurement is the most sensitive diagnostic test for post-ERCP pancreatitis. The results of the present large retrospective study demonstrated that serum lipase was a more effective marker than amylase for predicting post-ERCP pancreatitis both after diagnostic ERCP and after therapeutic ERCP, based on the area under the ROC curves. A further prospective study should be performed to confirm the superiority of serum lipase over amylase as a predictor of post-ERCP pancreatitis.

In conclusion, the 4-h post-ERCP serum amylase level and the 4-h post-ERCP lipase level, in particular, were found to be a useful means of predicting pancreatitis both after diagnostic ERCP and after therapeutic ERCP in a large retrospective study in a single center. A prospective study should be undertaken to confirm the usefulness of the 4-h post-ERCP amylase and lipase levels as predictors of post-ERCP pancreatitis.

5. References

[1] Wallner BK, Schumacher KA, Weidenmaier W, Friedrich JM. Dilated biliary tract: evaluation with MR cholangiography with a T2-weighted contrast-enhanced fast sequence. Radiology 1991;181:805-8
[2] Morimoto K, Shimoi M, Shirakawa T, Shirakawa T, Aoki Y, Choi S, et al. Biliary obstruction: evaluation with three-dimensional MR cholangiography. Radiology 1992;183:578-80

[3] Testoni PA, Mariani A, Giussani A, Vailati C, Masci E, Macarri G, et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol 2010;105:1753-61.

[4] Cotton PB, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc 2009;70:80-8.

[5] Gottlieb K, Sherman S. ERCP and endoscopic biliary sphincterotomy-induced pancreatitis. Gastrointest Endosc Clin N Am 1998;8:87-114

[6] Freeman ML, DaSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001;54:425-434

[7] Christoforidis E, Goulimarlis I, Kanellos I, Tsalis K, Demetriades C, Bettsis D. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy 2002;34:286-92

[8] Friedland S, Soetikno RM, Vandervoot J, Montes H, Tham T, Carr-Locke DL. Bedside scoring system to predict the risk of developing pancreatitis following ERCP. Endoscopy 2002;34:483-8

[9] Leperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998;48:1-10

[10] Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001;96:417-23

[11] Mehta SN, Pavone E, Barkun JS, Bouchard S, Barkun AN. Predictors of post-ERCP complications in patients with suspected choledocholithiasis. Endoscopy 1998;30:457-63

[12] Rabenstein T, Schneider HT, Bulling D, Nicklas M, Katalinic A, Hahn EG. Analysis of risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy 2000;32:10-19

[13] Vandervooit J, Soetikno RM, Tham TC, Wong RC, Ferrari AP Jr, Montes H, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002;56:652-6

[14] Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006;101:139-47

[15] Sherman S, Hawes RH, Rathgaber SW, Uzer MF, Smith MT, Khusro QE, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointest Endosc 1994;40:422-7

[16] Thomas P, Sengupta S. Prediction of pancreatitis following retrograde cholangiopancreatography by the 4-h post procedure amylase level. J Gastroenterology and Hepatology 2001;16:923-926.
[17] Ito K, Fujita N, Noda Y, Kobayashi G, Horaguchi J, Takasawa O, et al. Relationship between post-ERCP pancreatitis and the change of serum amylase level after the procedure. World J Gastroenterology 2007;13:3855-60.

[18] Testoni PA, Bagnolo F, Caporuscio S, Lella F. Serum amylase four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis. Am J Gastroenterology 1999; 94:1235-1241.

[19] Thomas P, Sengupta S. Prediction of pancreatitis following retrograde cholangiopancreatography by the 4-h post procedure amylase level. J Gastroenterology and Hepatology 2001;16:923-926.

[20] Apple F, Benson O, Preese L, Eastep S, Bilodeau L, Heiler G. Lipase and pancreatic amylase activities in tissue and in patients with hyperamylasemia. Am J Clin Pathol 1991;96:610-4.

[21] Nordestgaard AG, Wilson SE, Williams RA. Correlation of serum amylase levels with pancreatic pathology and pancreatitis etiology. Pancreas 1988;3:159-61.

[22] Levitt MD, Johnson SG. Is the Cam/CCr ratio of value for the diagnosis of pancreatitis? Gastroenterology 1978;75:118-9.

[23] Orebaugh SL. Normal amylase levels in the presentation of acute pancreatitis. Am J Emerg Med 1994;12:21-4.

[24] Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN guideline for the management of acute pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg 2006;13:25-32.

[25] Panteghini M, Pagani F, Alebardi O, Lancini G, Cestari R. Time course of changes in pancreatic enzymes, isoenzymes, and isoforms in serum after endoscopic retrograde cholangiopancreatography. Clin Chrm 1991;37:1602-5.

[26] Doppl WE, Weber H, Temme H, Klör HU, Federlin K. Evaluation of ERCP- and endoscopic sphincterotomy-induced pancreatic damage: A prospective study on the time course and significance of serum levels of pancreatic secretory enzymes. Eur J Med Res 1996;1:303-11.

[27] Kapetanos D, Kokozidis G, Kinigopoulou P, Xiarchos P, Antonopoulous Z, Proqia E, et al. The value of serum amylase and elastase measurements in the prediction of post-ERCP acute pancreatitis. Hepato-gastroenterology 2007;54:556-560

[28] Ogawa M, Hirotta M, Hayakawa T, Matsuno S, Watanabe S, Atomi Y, et al. Development and use of a new staging system for severe acute pancreatitis based on a nationwide survey in Japan. Pancreas 2002;25:325-30

[29] Hirotta M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN guideline for management of acute pancreatitis: severity assessment of acute pancreatitis. J Hepatobiliary Pancreat Surg 2006;13:33-41.

[30] Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: A randomized, controlled trial. Clin. Gastroenterology and Hepatology 2005;3:376-83.

[31] Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.

[32] Gottlieb K, Sherman S, Pezzi J, Esber E, Lehman GA. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterology 1996;91:1553-7.
[33] Testoni PA, Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointestinal Endoscopy 2001;53:33-9.

[34] Nishino T, Toki F, Oyama H, Shiratori K. More accurate prediction of post-ERCP pancreatitis by 4-H serum lipase levels than amylase levels. Digestive Endoscopy 2008;20:169-177.
Pancreatitis may be acute or chronic. Although they can be caused by similar aetiologies, they tend to follow distinct natural histories. Around 80% of acute pancreatitis (AP) diagnoses occur as secondary to gallstone disease and alcohol misuse. This disease is commonly associated with the sudden onset of upper abdominal that is usually severe enough to warrant the patient seeking urgent medical attention. Overall, 10 to 25% of AP episodes are classified as severe, leading to an associated mortality rate of 7 to 30%. Treatment is conservative and consists of general medical support performed by experienced teams, sometimes in ICUs. Although most cases of acute pancreatitis are uncomplicated and resolve spontaneously, the presence of complications has significant prognostic importance. Necrosis, hemorrhage, and infection convey rates of up to 25%, 50%, and 80% mortality, respectively. Other complications such as pseudocyst formation, pseudoaneurysm formation, or venous thrombosis increase morbidity and mortality to a lesser degree. The presence of pancreatic infection must be avoided.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Takayoshi Nishino and Fumitake Toki (2012). Prediction of Post-ERCP Pancreatitis, Pancreatitis - Treatment and Complications, Prof. Luis Rodrigo (Ed.), ISBN: 978-953-51-0109-3, InTech, Available from: http://www.intechopen.com/books/pancreatitis-treatment-and-complications/prediction-of-post-ercp-pancreatitis